CAJ | 학술논문

目的观察常规剂量重组人促红细胞生成素(rHuEpo)联合健脾补肾益气养血方对化疗相关性贫血的疗效及其对生存质量的影响.方法选择2007年7月-2009年7月我院收治的166例化疗相关性贫血患者,将其随机分为治疗组和对照组,治疗组给予健脾补肾益气养血辨证方(1剂/d,最多8周)联合常规剂量的rHuEpo(10 000 U/次,皮下注射,3次/周,最多8周)治疗;对照组仅给予常规剂量的rHuEpo,观察两组患者治疗前后的血红蛋白(Hb)、血细胞比容(Hct)、一般行为状态(karnofsky performance status,KPS)评分的变化及不良反应.结果两组可评价疗效者共112例,治疗组和对照组分别为55例和57例.治疗第2、4、6、8周治疗组患者的Hb、Hct水平(除治疗第6周的Hct外)与对照组比较,差异有统计学意义(P<0.05);且均较治疗前显著升高(P<0.05).治疗组贫血治疗的有效率为76.4%,对照组为54.4%,差异有统计学意义(P<0.05).两组患者治疗前KPS评分均为(70±10)分,治疗后治疗组为(90±5)分,对照组为(80±10)分,差异有统计学意义(P<0.05).两组治疗后各种不良反应发生率间差异无统计学意义(P>0.05).结论 rHuEpo联合健脾补肾益气养血辨证方治疗化疗相关性贫血的疗效显著优于单用rHuEpo治疗,且能显著改善患者的生活质量.
목적 관찰상규제량중조인촉홍세포생성소(rHuEpo)연합건비보신익기양혈방대화료상관성빈혈적료효급기대생존질량적영향.방법 선택2007년7월-2009년7월아원수치적166례화료상관성빈혈환자,장기수궤분위치료조화대조조,치료조급여건비보신익기양혈변증방(1제/d,최다8주)연합상규제량적rHuEpo(10 000 U/차,피하주사,3차/주,최다8주)치료;대조조부급여상규제량적rHuEpo,관찰량조환자치료전후적혈홍단백(Hb)、혈세포비용(Hct)、일반행위상태(karnofsky performance status,KPS)평분적변화급불량반응.결과 량조가평개료효자공112례,치료조화대조조분별위55례화57례.치료제2、4、6、8주치료조환자적Hb、Hct수평(제치료제6주적Hct외)여대조조비교,차이유통계학의의(P<0.05);차균교치료전현저승고(P<0.05).치료조빈혈치료적유효솔위76.4%,대조조위54.4%,차이유통계학의의(P<0.05).량조환자치료전KPS평분균위(70±10)분,치료후치료조위(90±5)분,대조조위(80±10)분,차이유통계학의의(P<0.05).량조치료후각충불량반응발생솔간차이무통계학의의(P>0.05).결론 rHuEpo연합건비보신익기양혈변증방치료화료상관성빈혈적료효현저우우단용rHuEpo치료,차능현저개선환자적생활질량.
Objective To investigate the therapeutic effect of recombinant human erythropoietin(r-HuEpo) combined with Jianpi-Bushen-Yiqi-Yangxue Recipe(JBYYR) in treating chemotherapy-related anemia,and its impact on patients′ quality of life.Methods One hundred sixty-six chemotherapy-related anemia patients admitted from July 2007 to July 2009 were randomly divided into groups treatment and control.The treatment group received JBYYR(1 recipe,qd,less than 8 weeks) and R-HuEpo (10000u,qod,Subcutaneously,less than 8 weeks),while the control only R-HuEpo in the same dosage.The changes of hemoglobin (Hb),hematocrit (Hct) and Karnofsky performance status (KPS) and and their adverse reactions were observed.Results The levels of Hb,Hct,KPS increased in 2 groups after treatment as compared with pretreatment.The effective rate of anemia treatment was 76.4% in treatment group and 54.4% in control (P<0.05).The KPS scores were 70±10 in 2 groups before treatment,but after treatment,90±5 in treatment group, 80±10 in control,the difference was significant (P<0.05).There was not significant difference in incidence of adverse reactions between 2 groups (P>0.05).Conclusion Combined use of r-HuEpo and JBYYR,effecting better than single-use r-HuEpo,can improve significantly patients′ qulity of life.